3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Cited by 106 Publications

Acta Neuropathol, 2019, 138(1):67-84

PubMed: 30937520 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Cell Death Differ, 2019, 26(6):1077-1088

PubMed: 30341420 ( click the link to review the publication )

Mol Cancer, 2019, 18(1):82

PubMed: 30953511 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(9):1282-1297

PubMed: 30767208 ( click the link to review the publication )

Cell Prolif, 2019, 52(3):e12576

PubMed: 30719778 ( click the link to review the publication )

Cells, 2019, 8(3)

PubMed: 30875964 ( click the link to review the publication )

Cells, 2019, 8(5)

PubMed: 31130711 ( click the link to review the publication )

J Immunol, 2019, 10.4049/jimmunol.1900169

PubMed: 31235551 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28432

PubMed: 30847932 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28382

PubMed: 30793300 ( click the link to review the publication )

J Cell Physiol, 2019, 234(3):2778-2787

PubMed: 30145832 ( click the link to review the publication )

Exp Neurol, 2019, 311:44-56

PubMed: 30219731 ( click the link to review the publication )

Front Oncol, 2019, 9:387

PubMed: 31157167 ( click the link to review the publication )

Front Cell Neurosci, 2019, 10.3389/fncel.2018.00515

PubMed: 30692914 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(4):882-894

PubMed: 30906218 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:175

PubMed: 31320837 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:7

PubMed: 30627053 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108911

PubMed: 31079001 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:5197-5208

PubMed: 31239774 ( click the link to review the publication )

Drug Metab Dispos, 2019, 47(4):425-435

PubMed: 30745309 ( click the link to review the publication )

Cell Signal, 2019, 53:327-338

PubMed: 30389500 ( click the link to review the publication )

Brain Res Bull, 2019, 150:1-12

PubMed: 31082455 ( click the link to review the publication )

Cell Biosci, 2019, 9:13

PubMed: 30680089 ( click the link to review the publication )
Prostate, 2019, 79(2):206-214

PubMed: 30345525 ( click the link to review the publication )

J Physiol Sci, 2019, 69(2):263-280

PubMed: 30374841 ( click the link to review the publication )

Chem Biol Interact, 2019, 300:18-26

PubMed: 30611790 ( click the link to review the publication )

Am J Transl Res, 2019, 11(3):1327-1342

PubMed: 30972165 ( click the link to review the publication )

Am J Transl Res, 2019, 11(4):2042-2055

PubMed: 31105816 ( click the link to review the publication )

Exp Eye Res, 2019, 184:126-134

PubMed: 31018117 ( click the link to review the publication )

Toxicol In Vitro, 2019, 55:43-50

PubMed: 30496793 ( click the link to review the publication )

Int J Mol Med, 2019, 43(3):1331-1342

PubMed: 30747215 ( click the link to review the publication )

Int J Mol Med, 2019, 44(2):457-468

PubMed: 31173197 ( click the link to review the publication )

Biosci Rep, 2019, 39(6)

PubMed: 31123166 ( click the link to review the publication )

Neurochem Res, 2019, 44(8):2007-2019

PubMed: 31325156 ( click the link to review the publication )

Neurochem Res, 2019, 44(5):1090-1100

PubMed: 30712242 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 516(4):1265-1271

PubMed: 31301767 ( click the link to review the publication )

Microb Pathog, 2019, 120-127

PubMed: 30910719 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 508(3):682-689

PubMed: 30528392 ( click the link to review the publication )

Exp Ther Med, 2019, 17(4):2425-2432

PubMed: 30906429 ( click the link to review the publication )

Viruses, 2019, 11(6)

PubMed: 31174294 ( click the link to review the publication )

Redox Biol, 2018, 18:138-157

PubMed: 30014903 ( click the link to review the publication )

Cancer Lett, 2018, 416:24-30

PubMed: 29246644 ( click the link to review the publication )

Cardiovasc Res, 2018, 114(7):1016-1028

PubMed: 29529137 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):156

PubMed: 30012194 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1063

PubMed: 30337536 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800463

PubMed: 29912588 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 46(3):975-985

PubMed: 29680838 ( click the link to review the publication )
Cancer Sci, 2018, 109(9):2706-2716

PubMed: 29945297 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386287 ( click the link to review the publication )

Biomed Pharmacother, 2018, 99:271-277

PubMed: 29334671 ( click the link to review the publication )

Int J Oncol, 2018, 53(1):215-224

PubMed: 29693166 ( click the link to review the publication )

J Environ Sci (China), 2018, 66:182-187

PubMed: 29628085 ( click the link to review the publication )

Brain Res Bull, 2018, 139:105-113

PubMed: 29452253 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):291-298

PubMed: 29355493 ( click the link to review the publication )

Chem Biol Interact, 2018, 281:11-23

PubMed: 29247643 ( click the link to review the publication )

Am J Transl Res, 2018, 10(4):1229-1236

PubMed: 29736216 ( click the link to review the publication )

Exp Gerontol, 2018, 114:57-66

PubMed: 30399406 ( click the link to review the publication )

Toxicol Lett, 2018, 289:28-41

PubMed: 29518472 ( click the link to review the publication )

Int Immunopharmacol, 2018, 64:308-318

PubMed: 30243066 ( click the link to review the publication )

Arch Biochem Biophys, 2018, 657:31-40

PubMed: 30222953 ( click the link to review the publication )

Drug Des Devel Ther, 2018, 12:2971-2980

PubMed: 30254426 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):3051-3062

PubMed: 29436589 ( click the link to review the publication )

DNA Cell Biol, 2018, 37(1):7-14

PubMed: 29068712 ( click the link to review the publication )

Exp Dermatol, 2018, 27(1):58-63

PubMed: 28767174 ( click the link to review the publication )

Cell Stress Chaperones, 2018, 23(1):1-12

PubMed: 28608264 ( click the link to review the publication )

Mol Med Rep, 2018, 17(3):4307-4316

PubMed: 29363725 ( click the link to review the publication )

Mol Med Rep, 2018, 18(2):1485-1494

PubMed: 29901107 ( click the link to review the publication )

Arch Med Res, 2018, 49(6):381-390

PubMed: 30573200 ( click the link to review the publication )

EBioMedicine, 2017, 17:45-56

PubMed: 28258923 ( click the link to review the publication )

Br J Cancer, 2017, 117(8):1139-1153

PubMed: 29017179 ( click the link to review the publication )

Front Immunol, 2017, 8:1507

PubMed: 29250056 ( click the link to review the publication )
J Cell Mol Med, 2017, 21(12):3420-3434

PubMed: 28643395 ( click the link to review the publication )

Food Chem Toxicol, 2017, 100:183-196

PubMed: 28025121 ( click the link to review the publication )

Cell Mol Neurobiol, 2017, 37(4):717-728

PubMed: 27430567 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:973-982

PubMed: 28292026 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:56

PubMed: 28293544 ( click the link to review the publication )

Food Funct, 2017, 8(12):4657-4667

PubMed: 29159335 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 87:54-68

PubMed: 28392376 ( click the link to review the publication )

J Cell Biochem, 2017, 119(7):5538-5550

PubMed: 29384220 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:431-439

PubMed: 28243065 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):487-493

PubMed: 28870808 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2017, 21(11):2604-2610

PubMed: 28678325 ( click the link to review the publication )

BMC Complement Altern Med, 2017, 17(1):538

PubMed: 29246220 ( click the link to review the publication )

Mol Med Rep, 2017, 16(5):7237-7244

PubMed: 28944847 ( click the link to review the publication )

Oncol Lett, 2017, 14(2):1959-1966

PubMed: 28789429 ( click the link to review the publication )

J BUON, 2017, 22(6):1554-1562

PubMed: 29332352 ( click the link to review the publication )

Comp Biochem Physiol C Toxicol Pharmacol, 2017, 195:52-59

PubMed: 28223193 ( click the link to review the publication )

Toxicol Res (Camb), 2017, 6(3):324-332

PubMed: 30090501 ( click the link to review the publication )

Theranostics, 2016, 6(12):2209-2224

PubMed: 27924158 ( click the link to review the publication )

Brain Pathol, 2016, 26(6):713-723

PubMed: 26613556 ( click the link to review the publication )

Free Radic Biol Med, 2016, 90:230-42

PubMed: 26593748 ( click the link to review the publication )

Cell Death Dis, 2016, 7(6):e2247

PubMed: 27253411 ( click the link to review the publication )

Cell Physiol Biochem, 2016, 38(6):2401-13

PubMed: 27299574 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:9460462

PubMed: 28119765 ( click the link to review the publication )

Int J Oncol, 2016, 48(4):1710-20

PubMed: 26892093 ( click the link to review the publication )
World J Gastroenterol, 2016, 22(18):4501-14

PubMed: 27182160 ( click the link to review the publication )

Am J Transl Res, 2016, 8(8):3593-602

PubMed: 27648150 ( click the link to review the publication )

Oncol Rep, 2016, 36(6):3363-3370

PubMed: 27779694 ( click the link to review the publication )

Int J Mol Med, 2016, 37(3):679-89

PubMed: 26847839 ( click the link to review the publication )

Int J Mol Med, 2016, 38(3):785-93

PubMed: 27431814 ( click the link to review the publication )

J Mol Neurosci, 2016, 58(4):401-10

PubMed: 26635026 ( click the link to review the publication )

J Biochem, 2016, 10.1093/jb/mvw040

PubMed: 27318358 ( click the link to review the publication )

Sci Rep, 2016, 6:33614

PubMed: 27647162 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(1):125-139

PubMed: 25628925 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

Vps34 ^[1] (HeLa cells)	PI3Kγ ^[1] (HeLa cells)
25 μM	60 μM

In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. ^[1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. ^[2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. ^[3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
95D	NX;3WpFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHEXWQ{dU1?	MoLuNog>	NXnJWIpYTE2VTx?=	NWDwOpVRemWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?=	NWP5bWhXOjV5MU[1OlE>
A549	M2nCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\hWVl{O22P	MWKybC=>	M{jrcGROW09?	NHTKbmZz\WS3Y3XzJIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldDDv[kBDTE2F	Mnz4NlU4OTZ3NkG=
95D	M3zocmFxd3C2b4Ppd{BCe3OjeR?=	MojJOY1O	MYSybC=>	NX;tcm5QTE2VTx?=	MUnpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh?	NIroTpQzPTdzNkW2NS=>
A549	MlfmRZBweHSxc3nzJGF{e2G7	MVK1cW0>	MmnWNog>	MkLsSG1UVw>?	MlmxbY5pcWKrdIOgRmROSy2rbnT1Z4VlKGGyb4D0c5Rq[yClZXzsJIRm[XSq	NUnFdGIyOjV5MU[1OlE>
NBL-W-S	M13OdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVy0clcxOW2P	Mn;ZOog>		MVjlcohidmOnczDHRW5VNTZzIITvfIlkcXS7	MmnkNlU{OjN{MkK=
NBL-W-S	Ml3yRZBweHSxc3nzJGF{e2G7	NYm0[mFMOW2P	NGXaOVM3cA>?		NHPjfWVqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBISU6WLU[x	NVn1UY5WOjV\|MkOyNlI>
A2780cp	NVew[3N{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDINY1O	NWrnZnpxOWh?		M1LVN4lv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp	MV6yOVMzOjZ7NB?=
A549	MV7GeY5kfGmxbjDBd5NigQ>?	NH7HeIs2dU1?	NVzqdHgzOmh?		NULMWpFZe3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK	MVKyOVI5PTZ{OB?=
H157	MmraSpVv[3Srb36gRZN{[Xl?	MUe1cW0>	Ml7GNog>		M4Hi[ZN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=>	MoDTNlUzQDV4Mki=
MDR	NXzOXXBRSXCxcITvd4l{KEG\|c3H5	NVzBOHVuOTCvTR?=	MkfrOog>		NF;GTY1{fHKnbnf0bIVveyC2aHWgdI94\XJib3[gZY51cWOjbnPldkBlenWpcx?=	M1;jd\|I2ODF7N{Cx
HT-29	NUDBSJdDSXCxcITvd4l{KEG\|c3H5	MY[xcW0>	MY[0PIg>	MlT3SG1UVw>?	M2j2T4VvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{	NXLPcXJnOjR6NEKxOVg>
Microglia	M4nRO2Fxd3C2b4Ppd{BCe3OjeR?=	MnLSOY1O	NF7KcmEzPGh?		M2DVPIRm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	M3\NdVI1QDF6NkCx
A2780cp	NFm3cFFCeG:ydH;zbZMhSXO\|YYm=	Mmf2Nk42dU1?	M3XXVVFp	Ml\U[IRJOk9?	MmrE[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	MXiyOFgyPzl2Nh?=
HepG2	NVr1[3Z[TnWwY4Tpc44hSXO\|YYm=	MnfwOY1O	MVi0bC=>		NGXoSYRqdmO{ZXHz[ZMhUExicnXs[YF{\Q>?	M2jlWVI1PzF\|NUi3
A549	MWjBdI9xfG:\|aYOgRZN{[Xl?	M4TJflVuVQ>?	NXm0W5YxPDiq		NILXVlVl\WO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubDDk[YF1cCCjbnSg[ZhxemW\|c3nvckBt\X[nbIOgc4Yh[2G\|cHHz[U0{NCCEZXPsbY4uOSCjbnSgUGM{NUmL	MmLJNlQ4ODZ\|MEO=
U2OS	NHji[pBCeG:ydH;zbZMhSXO\|YYm=	MVWxNI1O	MV2yOIg>		MYHpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g>	NF\Tc3QzPDZ\|OUCxNy=>
Saos-2	NYjGcHc2SXCxcITvd4l{KEG\|c3H5	NGD2e4gyOG2P	Mke1NlRp		NHP1O41qdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h?	NHzTTmIzPDZ\|OUCxNy=>
A549	M{XsXGFxd3C2b4Ppd{BCe3OjeR?=	MlrLNVBuVQ>?	M4q4e\|Q5cA>?		NIS3Vo5i[2OnbHXyZZRmeyC2aHWgdoVlfWO2aX;uJI9nKGOnbHygeoli[mmuaYT5JIlv\HWlZXSgZpkhWFS[	M1G3cVI1PjJ4N{Ky
HCT116	MonwRZBweHSxc3nzJGF{e2G7	M133c\|VuVQ>?	MmW2NlRp		NGjaeJJmdmijbnPld{B1cGViYYDvdJRwe2m\|IHnu[JVk\WRiYomgZZBq\2WwaX6=	M1PmRlI1PjJ4NUKy
HGC-27	M{X6W2Z2dmO2aX;uJGF{e2G7	Mk\2NVBuVQ>?	NIC2fYQycA>?		M4DZWYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBtd3O\|IHL5JHJCTDByMTDvdkBOUy1{MkC2	MXWyOFQyPjN2OR?=
U2OS	MYPGeY5kfGmxbjDBd5NigQ>?	M4Djd\|AvPS9zbV2=	MoO3OFhp		M1WyW4lv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{	NYj4c4J[OjR\|NUizOFI>
MG-63	NXzGU4lqTnWwY4Tpc44hSXO\|YYm=	MYewMlUwOW2P	MnP4OFhp		M{j6OYlv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{	NG\FemozPDN3OEO0Ni=>
MG-63	M3m1SGFxd3C2b4Ppd{BCe3OjeR?=	MlXCNE42NzGvTR?=	M4HmUlMzcA>?		NIDyN49mdmijbnPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygZZBweHSxc3nz	MkXGNlQ{PTh\|NEK=
MG-63	M2DhcmFxd3C2b4Ppd{BCe3OjeR?=	MoS3NVBuVQ>?	NXz2d\|NFOTKq		MYnlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=>	NYq3VXk1OjR\|NUizNFE>
NTUB1	NI\XTIlCeG:ydH;zbZMhSXO\|YYm=	Ml3mOY1O	NUC1b2xiOS53aB?=		MlzGdI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{	MXWyOFM1QTF5Nh?=
T24	NVWwUo1vSXCxcITvd4l{KEG\|c3H5	MWi1cW0>	NVLpZohWOS53aB?=		MVvwc5RmdnSrYYTld{Bk\WynY3;4bYIucW6mdXPl[EBieG:ydH;zbZM>	MXOyOFM1QTF5Nh?=
SGC-7901	MmO1RZBweHSxc3nzJGF{e2G7	NYi2[4tOOm2P	MYKxbC=>		MVHpcoNz\WG\|ZYOgR2EuPCCrbnT1Z4VlKGGyb4D0c5Nqew>?	NGixSmIzPDN{MUO0NC=>
SMMC-7721	MkO3RZBweHSxc3nzJGF{e2G7	MUOycW0>	NYnFe3JYOWh?		NUnWOmRYcW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:\|aYO=	NXG0XlJ3OjR\|MkGzOFA>
ECSCs	NYrObmtSSXCxcITvd4l{KEG\|c3H5	NHjjcmgyOG2P	MYi0bC=>		M1G1TIRm[3KnYYPld{Bz[XCjbYnjbY4ufHKnYYTl[EBieG:ydH;zbZM>	NV\tVZZEOjR\|MUmxNFk>
MCF-7	M{HXV2Z2dmO2aX;uJGF{e2G7	NWjHZpk2OTCvTR?=	MVqyOIg>		M2HC[4lvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDjbIVud3SqZYLhdJkh\HK3Z4O=	M{DF[FI1OzF3NUe4
UOK257	MYXBdI9xfG:\|aYOgRZN{[Xl?	MnvhOY1O	M1LzNVNp		MWPlcohidmOnczDwZYNtcXSjeHXsMY1m\GmjdHXkJIFxd3C2b4Ppd:Kh	M1j6ZlI1OzB3NkC0
ACHN-5968	NX32V2hqSXCxcITvd4l{KEG\|c3H5	M4Gy[\|VuVQ>?	NFXQS5M{cA>?		NFP4cHlmdmijbnPld{Bx[WOuaYThfIVtNW2nZHnheIVlKGGyb4D0c5Nqe8Li	MnrSNlQ{ODV4MES=
Huh7	NH3rV5JCeG:ydH;zbZMhSXO\|YYm=	MkLZNo1O	MWmxNog>	NFLBOW9FVVOR	MW\pcohq[mm2czDBXmQ5ODV3LXnu[JVk\WRiY3XscEBl\WG2aB?=	NWT2RVNxOjR{OUezNFA>
Hep3B	M4C3bmFxd3C2b4Ppd{BCe3OjeR?=	MWKycW0>	M1XaXVEzcA>?	MorySG1UVw>?	MXPpcohq[mm2czDBXmQ5ODV3LXnu[JVk\WRiY3XscEBl\WG2aB?=	NITVPHQzPDJ7N{OwNC=>
RKO	NYLPSZhsTnWwY4Tpc44hSXO\|YYm=	NGniXIYzdU1?	MV2xbC=>	Mk[wSG1UVw>?	MkPi[Y5p[W6lZYOgZ4VtdCCmZXH0bEBjgSCpZXzkZY5idXmlaX6=	NIrh[ogzPDJ7MUe3Oy=>
HepG2 E47	MknvSpVv[3Srb36gRZN{[Xl?	NFG2elQzNjWvTR?=	M2TaS\|Q5cA>?		MkSxbY5kemWjc3XzJJRp\SC2b4jpZ4l1gSCxZjDBRUwhSlORLDDhcoQhS0OuNB?=	NIPrcWczPDJ5M{ezPC=>
LoVo	MknlRZBweHSxc3nzJGF{e2G7	NUTBUnNyPW2P	NYO4SIh7PDiq		M4TTXoVvcGGwY3XzJGRESS2rbnT1Z4VlKGGyb4D0c5Nqey5?	NILPcFEzPDJyMUixNi=>
WiDr	NFS4VotHfW6ldHnvckBCe3OjeR?=	NFzHdYYyOG2P	M1XwbVFp		NXTQVYZWcW6qaXLpeJMhWEOETD3pcoR2[2WmIFzDN{BKUSCneIDy[ZN{cW:w	MnHWNlQyQTB2OEm=
H1299	NVnXXVlQTnWwY4Tpc44hSXO\|YYm=	NX\WenEzOTCvTR?=	NUjMbIdMPGh?		NUKx[lY5cW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh?	M4nxTVI1OTd\|MkC4
H460	M1noOmZ2dmO2aX;uJGF{e2G7	NGnWWGUyOG2P	NXvBPIpSPGh?		MUfpcoNz\WG\|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	M2G1UFI1OTd\|MkC4
A549	M1yxVmZ2dmO2aX;uJGF{e2G7	NY\4WIVDOTCvTR?=	MYK0bC=>		NXf5OZRQcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliaYLyZYRq[XSrb36=	NFH5SJYzPDF2MkezOS=>
Hep3B	MljRRZBweHSxc3nzJGF{e2G7	MUm1cW0>	MUKyOIg>		NGjhNmtifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM>	MVeyOFA3PjZ7Mx?=
SMMC-7721	NXTmfmtGSXCxcITvd4l{KEG\|c3H5	NUjUenhPPW2P	NIDVWlgzPGh?		NH\5cmVifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM>	Mn;1NlQxPjZ4OUO=
HO8910	M2L5[mFxd3C2b4Ppd{BCe3OjeR?=	MW[xNI1O	M2rlflEzcA>?		M3HmRoVvcGGwY3XzJGIyQS2rbnT1Z4VlKGGyb4D0c5Nq	M1nNbFI{QTh\|NkGw
MCF7	NWCxeW9oTnWwY4Tpc44hSXO\|YYm=	NGLGNWY2dU1?	NWnRZYhTOjSq		M1vyTIlv[3KnYYPld{BEfU9iaX7keYNm\CClZXzsJIRm[XSq	NFLHZXczOzl4Mk[yPS=>
HONE-1	MlPNSpVv[3Srb36gRZN{[Xl?	NVH2e3F3PW2P	MVWxbC=>		M2ToWZJmeHKnc4Pld{A3ei2vZXTpZZRm\CCUT2OgdJJw\HWldHnvci=>	MoTxNlM5QTJ\|NUi=
HeLa	NGnzWJRHfW6ldHnvckBCe3OjeR?=	M2rHclExdU1?	M1\oWFJp		NGSzU4t{fXCycnXzd4V{KEyFMzDJTUBmgHC{ZYPzbZNwdg>?	NVK2dIhJOjN6NkS3N\|g>
HepG2	MXrGeY5kfGmxbjDBd5NigQ>?	M1LmVVExdU1?	M{eyVFI1cA>?		MlG3bY5pcWKrdIOgd4lVUUeDUj2gZY5lKEiEU2OtbY5lfWOnZDDheZRweGijZ4m=	MV6yN\|gyPzB2MB?=
SH-SY5Y	NXHlWJBITnWwY4Tpc44hSXO\|YYm=	NFPudXAydU1?	MXmyOIg>		MmHpbY5pcWKrdIOgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IGTPR3A>	MlSzNlM4PDNzNEi=
SH-SY5Y	NUmxdJJbSXCxcITvd4l{KEG\|c3H5	NF;QdpI2dU1?	MYixbC=>		M3;iR4Fjd2yrc3jld{Bk\Wyjc4Tyc4whdmW3cn;wdo91\WO2aY\lJIVn\mWldB?=	MVeyN\|YyQTN7NR?=
PC12	M4D6TWZ2dmO2aX;uJGF{e2G7	NFT1cHgyOG2P	NYHG[HFYOjSq	NGjBVXR4[XSnch?=	MVhCpIlvcGmkaYTzJINpgW2xdIL5dJNqdi2uaXvlJJBzd3SnYYPvcYFtKGGldHn2bZR6Ng>?	MX[yN\|YxOzl5OR?=
OV2008	NYDDTmhtSXCxcITvd4l{KEG\|c3H5	NF:zSVg2dU1?	M{[wNVI1cA>?		M1Ln[oNwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy\|	M3G4ZlI{PTl{Mkix
A2780	NX;UbJZ2SXCxcITvd4l{KEG\|c3H5	MmfvOY1O	M2fZWFI1cA>?		MWLjc453\XK2czDGWHk4OjBid3n0bEBETESSIHnueI8h[W5iYXTkbZRqfmViZX\m[YN1KHSxd3Hy[JMhc2mubHnu[{BwfmG{aXHuJINidmOncjDj[Yxtew>?	MX[yN\|U6OjJ6MR?=
Saos-2	MkDQRZBweHSxc3nzJGF{e2G7	NFruR5QydU1?	NUXpcFVEQT[q		M2[3OIlv[3KnYYPld{Bk\WyuIHTlZZRpKGmwZIXj[YQh[nliUFPY	NHL5TpQzOzV4M{G3NS=>
1321N1	NGjQZWZEgXSxdH;4bYNqfHliQYPzZZk>	NFL6b2U2dU1?	NIO1TYwzPGh?		MkLMdJJwfGWldIOgZ4VtdCCjZ3HpcpN1KFCFTj3pcoR2[2WmIITvfIlkcXS7	NInU[\|czOzV{NUK2OS=>
SH-SY5Y	M3;IeWN6fG:2b4jpZ4l1gSCDc4PhfS=>	NGHRXIE2dU1?	NF7sd4wzPGh?		MXTpcoNz\WG\|ZYOgVGNPKHSxeHnjbZR6	MYmyN\|UzPTJ4NR?=
HT-29	MkC1SpVv[3Srb36gRZN{[Xl?	M1G5O\|FuVQ>?	Mn7sOFgwQT[q		MUHpcohq[mm2czDBUXBMKGmwZIXj[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq	MWSyN\|UxQDJ5Mh?=
OR6	MXrGeY5kfGmxbjDBd5NigQ>?	NGDYXXkyOG2P	NHT0UJc4Omh?		MVrzeZBxemW\|c3XzJGhEXiC{ZYDsbYNifGmxbjDhcoQh\m:{bXH0bY9vKG:oIHH1eI9xcGGpb4PvcYV{	Ml;oNlM{QTV6N{W=
Hela	NXfsfJdZTnWwY4Tpc44hSXO\|YYm=	NGr3XFE2dU1?	Mn;6NlRp		MXPpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5	NYHpemZQOjN\|OUW2O\|k>
MCF-7	MnmySpVv[3Srb36gRZN{[Xl?	MkHlOY1O	MXqyOIg>		MUPpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5	NGrxVWkzOzN7NU[3PS=>
HUVECs	MUPGeY5kfGmxbjDBd5NigQ>?	MVGzcW0>	M3eySVI1cA>?		MmqyZoxw[2u\|IITo[UBxem:2ZXP0bZZmKGWoZnXjeEBw\iC{ZYP2[ZJifHKxbDDifUBqdmirYnn0bY5oKGG3dH;wbIFogQ>?	M324OFI{OzV6OUK4
T24	NIHlbpdHfW6ldHnvckBCe3OjeR?=	NHnkNGoyOG2P	NXr2NGk{OWh?		MnLFdoVlfWOnczD0bIUh[2ynYY\h[4Uhd2ZiTFOzJIFnfGW{IHLhbYNidGmwIITy[YF1dWWwdB?=	NYTWSlVFOjN\|NUSwPFA>
U251MG	Mny0SpVv[3Srb36gRZN{[Xl?	MU[zcW0>	NVHHSXlxOWh?		MnHHd5VxeHKnc4Pld{BNSzNvSVmgdJJwfGWrbjDlfJBz\XO\|aX;u	Ml;oNlM{Ozh4MUi=
GTL-16	MWPBdI9xfG:\|aYOgRZN{[Xl?	NEPMTYI2dU1?	NXfBOWo4OjSq		NIHXRlRz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHzJINwdXCjcnXkJJRwKGOnbHzzJJRz\WG2ZXSge4l1cCCPRWSgbY5pcWKrdH;ydy=>	M3LIb\|I{OzF\|NEmw
T-47D	MkmySpVv[3Srb36gRZN{[Xl?	NYnuOnVzOTCvTR?=	MlTLNog>		MVXpcohq[mm2czDheZRweGijZ4mgdJJw[2W\|czDhcoQhcW6lcnXhd4V{KHKjcHHtfYNqdiCrbnT1Z4VlKGGyb4D0c5Nqew>?	MkHNNlM{ODByMk[=
PaCa44	MV3BdI9xfG:\|aYOgRZN{[Xl?	NIn0PI0zNjWvTR?=	MkK0NYg>		NXq4U3NUemWmdXPld:Kh\2WwaYDpck1u\WSrYYTl[EBieG:ydH;zbZM>	MWCyN\|EzPDFzMh?=
MDA-MB231	MVHGeY5kfGmxbjDBd5NigQ>?	NXnwbXdtPW2P	MmDtNYg>		NX;EVoJVcW6lcnXhd4V{KHKnc4\ldoF1em:uLX3l[IlifGWmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>?	NV\xXY1JOjNyOEi4OVA>
HeLa	MVzBdI9xfG:\|aYOgRZN{[Xl?	MkPYNVBuVQ>?	MmX0Nog>		Mn7N[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHPvMZRz\WG2bXXueEB4cXSqIGDFTS=>	NUX6fINoOjNyMECxN\|U>
SK-HEP-1	MUHBdI9xfG:\|aYOgRZN{[Xl?	MVuxNI1O	MkC0NYg>		NWXmSohweHKxdHXjeJMh[WejaX7zeEBifXSxcHjh[5kh[W6mIHnu[JVk\XNiYYDvdJRwe2m\|IHnuJIJ2\mGuaX6teJJm[XSnZDDj[Yxtew>?	NXzCNYNSOjJ6NUi2OFk>
HepG2	NUSwUnE{SXCxcITvd4l{KEG\|c3H5	M3fjPFNuVQ>?	M4ntWlVp		MUHy[YR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwZIXj[YQh[nliUVTz	MnjLNlI5OzZ3OUW=
MCF-7	Mk\KSpVv[3Srb36gRZN{[Xl?	NV\OfXl6Om2P	M1TFRlI1cA>?		NV3WNIFKcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=>	MWOyOFk4ODZ5Nh?=
MDA-MB-231	Ml63SpVv[3Srb36gRZN{[Xl?	NET6SlEzdU1?	NHv5TWszPGh?		NV[zZotFcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=>	MXKyOFk4ODZ5Nh?=
MCF-7	M1Gw[WZ2dmO2aX;uJGF{e2G7	MXyycW0>	Mo\EOFhp		M33K[pBzd22xdHXzJHRONWmwZIXj[YQh[2WubDDk[YF1cA>?	MoTGNlQ6PzB4N{[=
MDA-MB-231	MXvGeY5kfGmxbjDBd5NigQ>?	MoD6No1O	NHHyXZo1QGh?		NUfLb5BpeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq	MXWyOFk4ODZ5Nh?=
PANC-1	Ml3BRZBweHSxc3nzJGF{e2G7	MnPMNY1O	NELxd4s1QGh?	M3vmT2ROW09?	MmfW[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M>	NXnvVJlGOjR6NEKxOVg>
MDA-MB 231	M4Xa[GFxd3C2b4Ppd{BCe3OjeR?=	M{nMT\|VuVQ>?	Mo\jNE42cA>?		NEnvNYFud2S3bHH0[ZMhXG:lb33pcuKvyqCrbnT1Z4VlKGGyb4D0c5Nqew>?	NHPsWG0zPDh\|MEe4NS=>
Microglia	NW\1Zo1YSXCxcITvd4l{KEG\|c3H5	MnK5OY1O	NWn2VYRqOjSq		NHn4PWZl\WO{ZXHz[ZMhcHmyb4jpZU1qdmS3Y3XkJINmdGxiZHXheIg>	NGThWYMzPDhzOE[wNS=>
A2780cp	NXTrTIg6SXCxcITvd4l{KEG\|c3H5	MUmyMlVuVQ>?	NWHITG1vOWh?	MmjS[IRJOk9?	NGXZe2RmdmijbnPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp	MkH2NlQ5OTd7NE[=
HepG2	NUjCNIRjTnWwY4Tpc44hSXO\|YYm=	NH3rSpY2dU1?	NGnNdYM1cA>?		Mlz3bY5kemWjc3XzJINmdGy3bHHyJIxmfmWuczDv[kBJVMLi	NHjMe4MzPDdzM{W4Oy=>
U2OS	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDBNVBuVQ>?	Ml6yNlRp		M4LUc4lvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDpcoR2[2WmIHL5JGRwgA>?	NWn2SGYzOjR4M{mwNVM>
HCT116	NWDmUIlMSXCxcITvd4l{KEG\|c3H5	NVnrVldYPW2P	NXLx[JVwOjSq	MnHiSG1UVw>?	M3G2[IVvcGGwY3XzJIFxcWenbnnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	MojxNlQ3OjZ3MkK=
MCF-7	NHn4NXJCeG:ydH;zbZMhSXO\|YYm=	M3S3VVAvOW2P	NUDZNFFsPmh?		MkD6[Y5p[W6lZYOgd4lzfGmwb3ytbY5lfWOnZDDhdI9xfG:\|aYO=	NUHScWdwOjJ5NUG5PFk>
PC-3	NIrTSYJCeG:ydH;zbZMhSXO\|YYm=	MmnLNo1O	MlK2Nog>		NULO[Io{cW6lcnXhd4V{KE:UST3pcoR2[2WmIHPlcIwh\GWjdHi=	NV3zXnZNOjJ5NEW1PFA>
U251	Mk[0RZBweHSxc3nzJGF{e2G7	NIXO[\|Y2dU1?	MYKyOIg>		NFm3NYdqdmO{ZXHz[ZMhWzFvaX7keYNm\CClZXzsJIRm[XSq	NXPuXHZEOjJ3N{m3PFg>
HeLa	Mnz1RZBweHSxc3nzJGF{e2G7	M2LwPFVuVQ>?	MnTQNlRp		MUDpcoR2[2W\|IHPhd5Bie2VvZHXw[Y5l\W62IHPlcIwh\GWjdHi=	NGXleWwzOjV2NUGyPC=>
A549	MXvGeY5kfGmxbjDBd5NigQ>?	MmDCNE4ydU1?	M2\oRVI1cA>?		NVSy[IlJe3WycILld5NmeyCVVUGxNlc1NWmwZIXj[YQh[2WubDDk[YF1cA>?	MUOyNlQ3Pjl4MB?=
pDCs	NFLJOFJHfW6ldHnvckBCe3OjeR?=	NWPjWnBuOTCvTR?=	MmjjNE42cA>?		MV5CpJJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDJSm4u\|rFiYomgd5NTVkF2MB?=	MWWyNlM6PjV7OR?=
BGC-823	NYL0dIpITnWwY4Tpc44hSXO\|YYm=	MYG1cW0>	MkTKNog>		MonQbY5pcWKrdIOgeIhmKHKjdHWgc4Yh[XW2b4DoZYdq[yClZXzsdy=>	NUfnR25OOjJ\|MkKxOVI>
U937	MYjGeY5kfGmxbjDBd5NigQ>?	NVHVfmd5Om2P	M1:0XlEzcA>?		NWnp[YZT\GWlcnXhd4V{KHSqZTDheZRweGijZ4mgdoF1cW0EoB?=	M37HXVIzOTV3MUWw
Marc-145	MlX5SpVv[3Srb36gRZN{[Xl?	MXS1cW0>	MVyxNk8zPC9\|Nni=		NHK5[lZz\WS3Y3XzJJRp\SCSUmLTWkB1cXSncoOgZY5lKHSqZTDwdo91\WmwIHX4dJJme3Orb36=	NV\6WI5yOjJzMUm5NFA>
HBx	M3q5SGFxd3C2b4Ppd{BCe3OjeR?=	NVnTOIdoOTCvTR?=	NVzX[ms4PDiq	MVXEUXNQ	M{jDe4lv[3KnYYPld{Bk\WyuIHTlZZRp	Mm\YNlIxOjByN{i=
MCF-7	MU\GeY5kfGmxbjDBd5NigQ>?	MUexNI1O	NGrnRZY1QGh?		NWK0VZlM[myxY3vzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KGKxcoTlfo9ucWJ?	M2jsS\|IyQTNzOUO3
RMPI8226	MUjGeY5kfGmxbjDBd5NigQ>?	NWW3VYk{PW2P	NHzZOIIycA>?		NFLTNYZ{fXCycnXzd4V{KHSqZTDs[ZZmdCCxZjDheZRweGijZ4mgeY5l\XJiboX0dolmdnRiZHXwcIV1cW:w	MoPoNlE6OTV4MkC=
PC12/TetOn	NYPDUIx7TnWwY4Tpc44hSXO\|YYm=	MoTENE4yNzGvTR?=	NHHOeFUyQGh?		NU\D[\|A4dGWjZIOgeI8h\|rFvc4nuLHdVMSCjY3P1cZVt[XSrb36sJJRwgGmlaYT5MEBidmRib3zp[49u\XJiZn;ycYF1cW:wwrC=	NFy0S5ozOTlyNk[1PS=>
HeLa	MVPDfZRwfG:6aXPpeJkhSXO\|YYm=	MnLwNo1O	M{nPN\|I1cA>?		NXnR[pd4cW6qaXLpeIV{KHSqZTDjfZRwfG:6aXPpeJkhd2Zic3nsbYJqdmmwIITvJGhmVGFiY3XscJMv	MUWyNVg4PTN6NR?=
Jurkat	MVTGeY5kfGmxbjDBd5NigQ>?	M3fGNlExdU1?	MWqxbC=>		M2[wfIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzNvSVmgZY5lKHSqZTDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO=	M4HyelIyQDZ2MEO3
K562	NFHrW4pHfW6ldHnvckBCe3OjeR?=	M2HI[FExdU1?	NYXCT\|l5OWh?		Ml3S[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?=	MWKyNVg3PDB\|Nx?=
Nara-H	NETZTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3ztOVVuVQ>?	NHz3T5M1QGh?		MVTlcohidmOnczD0[Y1{cXKxbHnteZNu\WSrYYTl[EB{fXCycnXzd4lwdiCxZjDOZZJiNUhiY3XscEBxem:uaX\ldoF1cW:w	MXKyNVgxPTB\|Mx?=
HUVECs	MYnGeY5kfGmxbjDBd5NigQ>?	Mmm1NVBuVQ>?	M4\ke\|AvPWh?		NWrEbW44\GWlcnXhd4V{KHSqZTDBS2UuSlODaX7keYNm\CCjdYTvdIhi\3libHX2[S=>	MVWyNVQ3QDV7Mh?=
HepG2	M2HuV2Fxd3C2b4Ppd{BCe3OjeR?=	NWTXWY1tOm2P	MYWxbC=>		MnH4[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	NFfiWokzOTR3M{[5NS=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; PubMed: 29296191 Oncotarget Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells. caspase-3 / caspase-9 / PARP; PubMed: 25891159 Mol Med Rep EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase. VEGF; PubMed: 25891159 Mol Med Rep Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor. APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; PubMed: 26316755 Neuropsychiatr Dis Treat Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.	29296191 25891159 26316755
Immunofluorescence	LC3 / Hif-α / COX2; PubMed: 29039446 Int J Mol Med Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.	29039446
Growth inhibition assay	Cell viability; PubMed: 26934124 Oncotarget KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.	26934124

In vivo

3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. ^[5]

Protocol

Kinase Assay:^[4]	+ Expand Protein degradation assay: HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U-¹⁴C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:^[2]	+ Expand Cell lines: HeLa cell line Concentrations: 1-10 mM Incubation Time: 24, 48 or 72 hours Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 10⁶/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer. (Only for Reference)
Animal Research:^[5]	+ Expand Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g Formulation: Saline Dosages: 400 nM Administration: Intracerebral ventricular (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	Water	10 mg/mL warmed (67.04 mM)
	Ethanol	4 mg/mL (26.81 mM)
	DMSO	3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download 3-Methyladenine (3-MA) SDF

Molecular Weight	149.15
Formula	C₆H₇N₅
CAS No.	5142-23-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC 66389

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution
Answer:
As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

BEZ235 (NVP-BEZ235, Dactolisib) : p110α/γ/δ/β, IC50=4 nM/5 nM/7 nM/75 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

VS-5584 (SB2343) ^New : Potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Dactolisib (BEZ235, NVP-BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

3-Methyladenine (3-MA)

Cited by 106 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download 3-Methyladenine (3-MA) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Choose Your Country or Region

By Signaling Pathways

By product type

3-Methyladenine (3-MA)

Cited by 106 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download 3-Methyladenine (3-MA) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)